<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26734">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900015</url>
  </required_header>
  <id_info>
    <org_study_id>STERAL/50410</org_study_id>
    <nct_id>NCT01900015</nct_id>
  </id_info>
  <brief_title>CHANGES IN LIVER STEATOSIS AFTER SWITCHING TO RALTEGRAVIR IN HIV/HCV COINFECTION</brief_title>
  <official_title>CHANGES IN LIVER STEATOSIS AFTER SWITCHING FROM EFAVIRENZ TO RALTEGRAVIR AMONG HIV/HCV-COINFECTED PATIENTS RECEIVING TWO NUCLEOSIDE ANALOGS PLUS EFAVIRENZ: THE STERAL STUDY.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan Macías</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andaluz Health Service</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to
      rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen
      on hepatic steatosis (HS) as measured by the controlled attenuation parameter (CAP) among
      HIV/HCV-coinfected patient.

      Secondary Trial Objective:

        1. To compare the proportion of HIV/HCV-coinfected patients with one category decrease in
           the grade of HS between patients continuing with EFV plus two nucleoside analogs and
           those switching from EFV plus two nucleoside analogs to RAL plus two nucleoside
           analogs.

        2. To evaluate the proportion of patients who maintain viral control  (HIV RNA &lt; 50
           copies/mL) after switching.

      Design:

      Open-label, randomized clinical trial to evaluate safety (phase IV)

      Condition:

      HIV and HCV coinfection.

      Intervention:

      Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV
      to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current
      regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to
      rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen
      on hepatic steatosis (HS) as measured by the controlled attenuation parameter (CAP) among
      HIV/HCV-coinfected patient.

      Secondary Trial Objective:

        1. To compare the proportion of HIV/HCV-coinfected patients with one category decrease in
           the grade of HS between patients continuing with EFV plus two nucleoside analogs and
           those switching from EFV plus two nucleoside analogs to RAL plus two nucleoside
           analogs.

        2. To evaluate the proportion of patients who maintain viral control  (HIV RNA &lt; 50
           copies/mL) after switching.

      Design:

      Open-label, randomized clinical trial to evaluate safety (phase IV)

      Condition:

      HIV and HCV coinfection.

      Intervention:

      Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV
      to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current
      regimen.

      Study population and sample size HIV-infected patients with concomitant coinfection by HCV,
      as shown by detectable plasma HCV RNA, not candidates for therapy against HCV infection
      during the 48 week period of the Number of patients to recruit: 96, 48 patients per
      treatment group should be recruited.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To compare the impact of switching from EFV plus two nucleoside analogs to RAL     plus two nucleoside analogs versus keeping the same antiretroviral regimen on HS as measured by CAP among HIV/HCV-coinfected patients.</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of patients who maintain viral control  (HIV RNA &lt; 50 copies/mL) after switching.</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>HCV Coinfection</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Each subject must be willing and able to provide written informed consent for the
             trial.

          2. Each subject must be ≥ 18 years of age.

          3. Each subject must be male or non-pregnant, non-breastfeeding female

          4. Each subject must have diagnosis of HIV infection.

          5. Each subject must have concomitant coinfection by HCV as shown by detectable plasma
             HCV RNA.

          6. Each subject must have stable treatment with EFV plus two nucleoside analogs for ≥24
             weeks.

          7. Each subject must have at least 2 documented plasma HIV RNA &lt;50 copies/ml during the
             last 24 weeks, as observed in, at least, two clinical visits.

          8. Each subject must have HS involving more than 10% of hepatocytes, as determined by a
             CAP measurement ≥238 dB/m.

          9. Each sexually active female subject of child-bearing potential must agree to use a
             medically accepted method of contraception while receiving protocol-specified
             medication and for 3 months after stopping the medication.Medically accepted methods
             of contraception include condoms (male or female) with or without a spermicidal
             agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, inert or
             copper-containing IUD, hormonereleasing IUD, systemic hormonal contraceptive, and
             surgical sterilization (eg,hysterectomy or tubal ligation).Postmenopausal women are
             not required to use contraception.Postmenopausal is defined as at least 12
             consecutive months without a spontaneous menstrual period.

         10. Each sexually active male subject with a female partner(s) of child-bearing potential
             must also provide written informed consent to provide information regarding any
             pregnancy.

         11. Average daily alcohol intake lower than 50 g for men and 40 g for women.

        Exclusion Criteria:

          1. The subject has an allergy/sensitivity to investigational product or its/their
             excipients.

          2. The female subject is nursing.

          3. The female subject is pregnant or intending to become pregnant.

          4. History of ARV failure or documented resistance.

          5. Baseline resistance to EFV or to any of the nucleoside analogues inhibitors in the
             regimen.

          6. The subject has any clinically significant condition or situation, other than the
             condition being studied that, in the opinion of the investigator, would interfere
             with the trial evaluations or optimal participation in the trial.

          7. The subject has active AIDS-defining event (CDC-C) within 24 weeks before screening.

          8. The subject is candidate for therapy against HCV infection during the 48 week trial
             period in the opinion of the investigator.

          9. The subject has a history of malignant neoplasia.

         10. Active illicit drug use or any other condition that may compromise the study drug
             adherence in the opinion of the investigators.

         11. The subject has used any investigational drugs within 30 days of Baseline.

         12. A subject who has participated in any other clinical trial within 30 days,inclusive,
             of signing the informed consent form of the current trial.

         13. The subject or a family member is among the personnel of the investigational or
             SPONSOR staff directly involved with this trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Macías, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases and Microbiology Unit. Hospital Universitario de Valme. Servicio Andaluz de Salud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Macías, PhD</last_name>
    <phone>955015736</phone>
    <phone_ext>315736</phone_ext>
    <email>juan.macias.sanchez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María Mancebo, Nurse</last_name>
    <phone>955015871</phone>
    <phone_ext>315871</phone_ext>
    <email>marmanher86@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital La Línea</name>
      <address>
        <city>La Línea de la Concepción</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Téllez</last_name>
      <email>ptellezp@terra.es</email>
    </contact>
    <investigator>
      <last_name>Francisco Téllez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Rivero</last_name>
      <email>ariveror@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Rivero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Elena</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dolores Merino</last_name>
      <email>merinolola080@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dolores merino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Omar Mohamed-Balghata</last_name>
      <email>omarampa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Omar</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mohamed Mohamed-Balghata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan González</last_name>
      <email>juangonzalezgar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Rubio García</last_name>
      <email>rafaelrubiog@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Pulido Ortega</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Rubio García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Márquez</last_name>
      <email>med000856@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Márquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcial Fernández</last_name>
      <email>med006803@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcial Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Fernando López Cortés</last_name>
      <email>lflopez@us.es</email>
    </contact>
    <investigator>
      <last_name>Luis Fernando López-Cortés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.U. Valme</name>
      <address>
        <city>Seville</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Mancebo, Nurse</last_name>
      <email>marmanher86@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan A Pineda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Macías, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Lozano, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramón Morillo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 15, 2013</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Andaluz Health Service</investigator_affiliation>
    <investigator_full_name>Juan Macías</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
